Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag:  a case report.

ABSTRACT:

Background

Pulmonary arterial hypertension is a progressive, debilitating condition characterized by increased resistance in the pulmonary arterial circulation. Current treatments for pulmonary arterial hypertension include endothelin receptor antagonists such as bosentan, sitaxentan, ambrisentan, macitentan, and oral prostacyclin receptor agonists such as selexipag. Endothelin receptor antagonists have been associated with liver injury, while hepatotoxicity was not reported for selexipag. Although genetic variability has been indisputably associated with variability in drug response, no study has been designed until now to assess its effects on the pharmacokinetics of endothelin receptor antagonists or selexipag.

Case presentation

We report the case of a 58-year-old female

SUBMITTER: Lattanzio M 

PROVIDER: S-EPMC9578229 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature